A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO)

References

• Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9
   PubMed Web of Science ®Google Scholar
• Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. 2010. Available at: http://www.rcophth.ac.uk/core/core_picker/download.asp?id=728&filetitle=Interim+Guidelines+for+Management+of+Retinal+Vein+Occlusion+2010. Accessed August 21, 2013
   Google Scholar
• Awdeh RM, Elsing SH, Deramo VA, et al. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 2010;94:319-23
   PubMed Web of Science ®Google Scholar
• Deramo VA, Cox TA, Syed AB, et al. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003;121:1297-302
   PubMed Web of Science ®Google Scholar
• The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82
   PubMed Web of Science ®Google Scholar
• Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28
   PubMed Web of Science ®Google Scholar
• Glanville J, Patterson J, McCool R, et al. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review. BMC Ophthalmology 2014;14:7
   PubMed Web of Science ®Google Scholar
• The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995;102:1425-33
   PubMedGoogle Scholar
• Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. TA 283. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. May 2013. Available at: http://www.nice.org.uk/nicemedia/live/14169/63851/63851.pdf. Accessed March 18, 2014
   Google Scholar
• McAllister IL, Gillies ME, Smithies LA, et al. The Central Retinal Vein Bypass Study: a trial of laser-induced chorioretinal venous anastomosis for central retinal vein occlusion. Ophthalmology. 2010;117:954-65
   PubMed Web of Science ®Google Scholar
• Lucentis® Summary of Product Characteristics. Availabile at: http://www.medicines.org.uk/emc/medicine/19409/SPC/Lucentis+10+mg+ml+solution+for+injection/. Last updated July 17, 2013.
   Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9
   PubMed Web of Science ®Google Scholar
• Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-9
   PubMed Web of Science ®Google Scholar
• Gangnon RE, Davis MD, Hubbard LD, et al. A severity scale for diabetic macular edema developed from ETDRS data. Invest Ophthalmol Vis Sci 2008;49:5041-7
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Last updated July 2013. Available at: http://www.nice.org.uk/aboutnice/howwework/devnicetech/guidetothemethodsoftechnologyappraisal.jsp. Accessed August 21, 2013
   Google Scholar
• Klein R, Klein BE, Linton KL, et al. The Beaver Dam Eye Study: visual acuity. Ophthalmology 1991;98:1310-5
   PubMed Web of Science ®Google Scholar
• Christ SL, Lee DJ, Lam BL, et al. Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling. Invest Ophthalmol Vis Sci 2008;49:3318-23
   PubMed Web of Science ®Google Scholar
• Cugati S, Cumming RG, Smith W, et al. Visual impairment, age-related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study. Arch Ophthalmol 2007;125:917-24
   PubMedGoogle Scholar
• Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology. 2007;114:520-4
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. TA 229. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. July 2011. Available at: http://www.nice.org.uk/guidance/TA229. Accessed August 21, 2013
   Google Scholar
• Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511
   PubMedGoogle Scholar
• Czoski-Murray C, Carlton J, Brazier J, et al. Valuing condition-specific health states using simulation contact lenses. Value Health 2009;12:793-9
   PubMed Web of Science ®Google Scholar
• Department of Health. NHS reference costs 2009–10. January 2011. Available at: https://www.gov.uk/government/publications/nhs-reference-costs-2009-2010. Accessed August 21, 2013
   Google Scholar
• Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201-4
   PubMed Web of Science ®Google Scholar
• Curtis L. Unit costs of health & social care 2011. Personal Social Services Research Unit. 2011. Available at: http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf. Accessed August 21, 2013
   Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60
   PubMed Web of Science ®Google Scholar
• Loewenstein A, Bandello F, Tufail A, et al. Design and rational of Como, a 12-month masked study that compares the safety and efficacy of Oozurdex® versus Ranibizumab in branch retinal vein occlusion. Proceedings of the 2nd World Congress on Controversies in Ophthalmology, 3–6 March 2011, Barcelona, Spain. Available at: http://www.comtecmed.com/cophy/2011/Uploads/assets/loewenstein.pdf. [Last accessed 12 December 2013]
   Google Scholar
• Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Available at: http://www.medicinescomplete.com. Accessed November 2012
   Google Scholar
• Schwander B, Gradl B, Zollner Y, et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe–the HEALTH model. Value Health 2009;12:857-71
   PubMed Web of Science ®Google Scholar